Saturday, May 25, 2019

The U.S. Food and Drug Administration on Friday approved Incyte Corp's treatment for acute Graft versus Host disease (GvHD), an inflammatory response by the immune system after a bone marrow transplant.


from Reuters: Health News https://reut.rs/2YFQp4e

Related Posts:

  • LATEST HEALTH NEWSIsraeli pharmaceuticals company PainReform has received approval from the U.S. Food and Drug Administration (FDA) to begin late-stage clinical studies for a pain relief drug that is a departure from opiate-based narcotics, it… Read More
  • LATEST HEALTH NEWSIsrael's Together Pharma said on Tuesday it will set up a new company with Premier Dead Sea to sell cosmetics based on cannabis and Dead Sea minerals. from Reuters: Health News https://ift.tt/2N0LZ22 … Read More
  • LATEST HEALTH NEWS(Reuters Health) - More than 16 years after cleanup was completed at the site of the September 11, 2001 attack on New York City's World Trade Center complex, many who worked at the disaster site still struggle with post-traum… Read More
  • LATEST HEALTH NEWS(Reuters Health) - Taking multivitamins and minerals does not reduce the risk of cardiovascular disease or associated deaths, according to a new review of existing research. from Reuters: Health News https://ift.tt/2ukBl… Read More
  • LATEST HEALTH NEWS(Reuters Health) - Hormones given to people to align their sex with their gender pose a significant risk of serious blood clots and stroke among transgender women, one of the largest studies of transgender patients has conclu… Read More

0 comments:

Post a Comment

Followers

Contact Form

Name

Email *

Message *

Popular Posts

FOLLOW BY EMAIL

Enter your email address:

Delivered by FeedBurner